"In 1996, shortly after we began tracking the pharmaceutical industry, we spent time looking at obesity research and the latest diet pills. In doing so, we noticed that a panel that was assembled by the government to develop a guideline for the overweight known as the Body Mass Index. And it was populated by experts, nearly all of whom had a financial tie to a drugmaker selling or developing such pills. The finding, of course, was not all that new, but the practice continues, according to a new study in BMJ, which examined panels responsible for generating clinical practice guidelines on screening and/or treatment for high cholesterol or diabetes in the US and Canada between 2000 and 2010. A good many of the panelists - and panel chairs - had conflicts of interest. But not all were disclosed."
Read article at pharmalot.com
See also Dr Briffa's recent article on conflicts of interest.